The efficacy and safety of caplacizumab in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura: an open-label phase 2/3 study

Caplacizumab is an anti-von Willebrand factor humanized single-variable-domain immunoglobulin fragment whose efficacy and safety in immune-mediated thrombotic thrombocytopenia purpura (iTTP) have been demonstrated in international studies. This prospective, open-label phase 2/3 study evaluated capla...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyakawa, Yoshitaka, Imada, Kazunori, Ichikawa, Satoshi, Uchiyama, Hitoji, Ueda, Yasunori, Yonezawa, Akihito, Fujitani, Shigeki, Ogawa, Yoshiyuki, Matsushita, Tadashi, Asakura, Hidesaku, Nishio, Kenji, Suzuki, Kodai, Hashimoto, Yasuhiro, Murakami, Hidenori, Tahara, Sayaka, Tanaka, Tomoyuki, Matsumoto, Masanori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9970947/
https://www.ncbi.nlm.nih.gov/pubmed/36427162
http://dx.doi.org/10.1007/s12185-022-03495-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9970947/
https://www.ncbi.nlm.nih.gov/pubmed/36427162
http://dx.doi.org/10.1007/s12185-022-03495-6

Ejemplares similares